Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Xenetic Biosciences, Inc.

NASDAQ: XBIO · Life Sciences · 4 alerts · CIK 1534525

Share price
$1.49Close, Nov 16
Market cap
$3.49M
Shares outstanding
2.34MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xenetic Biosciences, Inc. filings on SEC EDGAR ↗

8:36 AM ET 8-K
M&A Deal

Xenetic Biosciences M&A Deal with Santersus AG

Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.

Counterparty
Santersus AG

“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”

James Parslow, Interim Chief Executive Officer and Chief Financial Officer

“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”

James Parslow, Interim Chief Executive Officer and Chief Financial Officer
5:01 PM ET 10-Q
Financial Results

Xenetic Biosciences Q3 2026 Results: Net Loss of $1.7M, Loss Widens

Xenetic Biosciences reported a net loss of $3.1 million for the nine months ended September 30, 2026, compared to $2.1 million in the prior year period, driven primarily by a significant increase in general and administrative expenses. Total revenue, derived from royalties, remained relatively flat at $2.2 million for the nine-month period. The company ended the quarter with $5.8 million in cash and is focused on advancing its systemic DNase program into clinical trials.

Key figure
Net loss $1.7M
5:20 PM ET 8-K
M&A Deal

Xenetic Biosciences M&A Deal with Santersus AG

Xenetic Biosciences released an updated investor presentation regarding its pending share exchange transaction to acquire Santersus AG. The deal, originally announced on September 16, 2026, involves a proposed acquisition that will result in a combined company focused on advancing NET-targeted therapies for immune-driven diseases and cancer.

Counterparty
Santersus AG
7:01 AM ET 8-K
M&A Deal

Xenetic Biosciences M&A Deal with Santersus AG

Xenetic Biosciences entered into a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction. Upon closing, Santersus shareholders are expected to own approximately 85% of the combined company, which will focus on NET-targeting therapeutics and trade under the new ticker symbol SNTS.

Counterparty
Santersus AG
Earnings call
Sep 16, 2026, 8:30 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.